Publication Name	World Journal of Hepatology
Manuscript ID	15655
Country	United States

Received	2014-12-02 09:02
Peer-Review Started	2014-12-02 10:50
To Make the First Decision	2015-01-08 14:05
Return for Revision	2015-01-12 20:03
Revised	2015-02-03 12:40
Second Decision	2015-02-27 09:38
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-03-09 17:25
Articles in Press	2015-03-09 17:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-10 14:52
Publish the Manuscript Online	2015-04-19 17:46

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Meta-Analysis
Article Title	Impact of all oral anti-hepatitis C virus therapy: A meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Siddharth Bansal, Ashwani K Singal, Brendan M McGuire and Bhupinder S Anand
Funding Agency and Grant Number
Corresponding Author	Ashwani K Singal, MD, MS, Assistant Professor, Department of Gastroenterology and Hepatology, University of Alabama Birmingham, 1720 2nd Ave S, Birmingham, AL 35294, United States. ashwanisingal.com@gmail.com
Key Words	Hepatitis C; Meta-analysis; Direct acting antivirals; Oral agents; Newer agents; Hepatitis C virus
Core Tip	Data are rapidly evolving on the efficacy and safety of newer oral direct acting antivirals (DAAs) for treating hepatitis C virus (HCV) infection. Second generation and emerging DAAs are promising agents in HCV treatment, with a very high level of safety and efficacy. An important drawback is their high cost. However, the present meta-analysis shows that the cost per sustained virologic response for non responders (but not for naive patients) was lower compared to peg interferon alfa2a + ribavirin. This finding together with the superior safety profile and better compliance makes these drugs highly attractive.
Publish Date	2015-04-19 17:46
Citation	Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol 2015; 7(5): 806-813
URL	http://www.wjgnet.com/1948-5182/full/v7/i5/806.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i5.806

Full Article (PDF)	WJH-7-806.pdf
Full Article (Word)	WJH-7-806.doc
Manuscript File	15655-Review.docx
Answering Reviewers	15655-Answering reviewers.pdf
Audio Core Tip	15655-Audio core tip.mp3
Biostatistics Review Certificate	15655-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	15655-Conflict-of-interest statement.pdf
Copyright License Agreement	15655-Copyright assignment.pdf
Peer-review Report	15655-Peer-review(s).pdf
Scientific Misconduct Check	15655-Scientific misconduct check.pdf
Scientific Editor Work List	15655-Scientific editor work list.pdf